FMR1 and fragile X syndrome: Thus, our data suggest that the decrease in the H3K9me2 levels on the FMR1 gene in AZA/chaetocin- and AZA/DZNep-treated FXS cells may be responsible for their effect on delaying re-silencing after AZA withdrawal.